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Glanzmann thrombasthenia (GT) is an autosomal recessive disorderof platelet aggregation caused by quantitative or qualitativedefects in integrins αIIb and β3. These integrins are encoded by
the ITGA2B and ITGB3 genes and form platelet glycoprotein (GP)IIb/IIIa,
which acts as the principal platelet receptor for fibrinogen. Although there
is variability in the clinical phenotype, most patients present with severe
mucocutaneous bleeding at an early age. A classic pattern of abnormal
platelet aggregation, platelet glycoprotein expression and molecular stud-
ies confirm the diagnosis. Management of bleeding is based on a combi-
nation of hemostatic agents including recombinant activated factor VII
with or without platelet transfusions and antifibrinolytic agents.
Refractory bleeding and platelet alloimmunization are common complica-
tions. In addition, pregnant patients pose unique management challenges.
This review highlights clinical and molecular aspects in the approach to
patients with GT, with particular emphasis on the significance of multi-
disciplinary care. 
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ABSTRACT
Introduction
The Swiss pediatrician Eduard Glanzmann was the first to describe in 1918 a
type of purpura that presented with normal platelet count and size in patients
with absent/decreased clot retraction and prolonged bleeding time.1 In 1962, Caen
and Cousin described the lack of platelet aggregation with multiple agonists,2 and
a few years later correlated the platelet aggregation result with decreased platelet
fibrinogen and a slight reduction in clot retraction in individuals with Glanzmann
thrombasthenia (GT).3 The lack of one of the three major platelet surface glyco-
proteins in GT was reported by Nurden and Caen in 1974;4 several other scientists
subsequently identified this as the glycoprotein (GP) IIb/IIIa complex. Additional
studies with more advanced glycoprotein imaging techniques provided evidence
for the definition of two disease groups: type I with absent IIb/IIIa expression
(<5% of normal) and type II with reduced expression (5-20% of normal GP
IIb/IIIa).5 A third type (type III) has normal levels of integrin but the protein is non-
functional. 
Glanzmann thrombasthenia is considered a rare disease, defined in the United
States as those affecting less than 200,000 individuals.6 The exact incidence has
been difficult to calculate, but is estimated at one in 1,000,000. With an autosomal
recessive inheritance, males and females are affected equally. There is a world-
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wide distribution; however, a large proportion of the
cases have been described in selected populations such as
the French Romani,7 South Indian Hindus, Iraqi Jews, and
Jordanian nomadic tribes,8 in all of which consanguinity
is common. Type I is the most common subtype and
accounts for around 78% of patients with GT type II and
type III (functional variant in receptor) constituting
around 14% and 8% of cases, respectively.9
GPIIb/IIIa (integrin αIIbβ3) is a heterodimeric receptor
present in large quantities in the plasma membrane of
platelets. Activation of this integrin and binding of soluble
ligands [primarily fibrinogen, but also von Willebrand fac-
tor (vWF) and fibronectin] are essential for platelet aggre-
gation. In the resting state, the integrin has low affinity for
ligands. During platelet activation, driven by exposure to
soluble agonists or the subendothelial matrix, “inside out”
cellular signaling generates a conformational change in
GPIIb/IIIa that allows high affinity binding for fibrinogen,
which serves as a “bridge” to other activated platelets,
eventually forming the platelet plug. Protein kinase C
(PKC), diaglycerol-regulated guanine nucleotide exchange
factor I (CalDAG-GEFI or RASGRP2), and phosphoinosi-
tide 3-kinase (PI3K) participate in this signaling pathway.
Subsequent “outside in” signaling triggers additional gran-
ule secretion, cytoskeletal interactions (that allow for
platelet spreading), stabilization and clot retraction to con-
solidate the fibrin clot. Kindlins (including kindlin-3) and
talins are key regulators of integrin activation.10, 11
Glanzmann thrombasthenia is usually caused by
decreased or absent expression of αIIb or β3, abnormali-
ties in protein folding, defective post-translational pro-
cessing or transport of either integrin subunit causing
decreased surface expression, or abnormalities affecting
protein function. Other defects change integrin function
by altering the ligand binding pocket (interface between
αIIb and β3), which modifies the cytoplasmic domain
and affects binding of regulators, or locks the integrin in
the activated form. 
Molecular basis of Glanzmann thrombasthenia
The ITGA2B and ITGB3 genes are located on chromo-
somes 17q21.31 and 17q21.32, respectively, and are inde-
pendently expressed. GT is caused by pathogenic variants
in both alleles of either of the two genes; concomitant
pathogenic variants in both genes, but affecting only one
allele of each, is not known to cause GT. Due to the auto-
somal recessive inheritance, compound heterozygosity is
frequent, except in selected ethnic groups where
homozygosity is more likely due to consanguinity. A
higher percentage of pathogenic variants occur in
ITGA2B, likely because of the larger size of this gene with
30 exons encoding 1,039 amino acids, compared to
ITGB3 which is composed of 15 exons with 788 amino
acids.7 The clinical phenotypes associated with either
gene are indistinguishable.12
Pathogenic nonsense, missense and splice site variants
are common and large deletions and duplications,
although rare, have also been described.13 Pathogenic mis-
sense variants impair subunit biosynthesis in megakary-
ocytes or inhibit the transport of the pro-αIIbβ3 complex-
es from the endoplasmic reticulum (ER) to the Golgi
apparatus or the export of the mature complexes to the
cell surface. A large proportion of variants affect the β-
propeller region of αIIb and the epithelial growth factor
domains of β3.14
A different type of variant affecting specific regions of
these genes has been more recently described to cause a
mild autosomal dominant macrothrombocytopenia15 by
interfering with proplatelet formation.16 These “gain of
function” variants cause spontaneous activation of
GPIIb/IIIa (αIIbβ3) by affecting the cytoplasmic domains
or the membrane proximal residues in the extracellular
domains. The majority of these are in ITGB3 and affect
the MIDAS (metal ion dependent adhesion site), ADMI-
DAS (adjacent to MIDAS) or SyMBS (synergistic metal
ion binding site) regions. A small proportion have been
reported in ITGA2B and affect the conserved intracellular
GFFKR sequence.17
Clinical manifestations and diagnosis 
Bleeding phenotype
With integrins αIIb and β3 participating in primary
hemostasis, the bleeding manifestations are typically pur-
pura, epistaxis (60-80%), gum bleeding (20-60%), and
menorrhagia (60-90%). Gastrointestinal bleeding in the
form of melena or hematochezia is present in 10-20%,
and 1-2% develop intracranial hemorrhage.9
Mucocutaneous bleeding can be spontaneous or occur
after minimal trauma. Epistaxis is the most common
cause of severe bleeding, especially in the pediatric popu-
lation, and risk of severe nosebleeds decreases with age as
the septal arterial plexus becomes less friable and children
grow out of the habit of nose picking. Menorrhagia is
highly prevalent in affected females and there is a higher
risk of severe bleeding at the time of menarche due to the
prolonged estrogen influence on the proliferative
endometrium that occurs during anovulatory cycles.
Bleeding complications during pregnancy are uncommon;
however, the risk of obstetric hemorrhage at the time of
delivery and postpartum is high. Hematuria and sponta-
neous hemarthrosis have been described in some cases
but are not usually part of the bleeding phenotype. 
Several bleeding scores have been developed with the
goal of standardizing the assessment of bleeding and
facilitating the diagnosis of patients with a suspected
inherited bleeding disorder. These are useful tools that
assist in communication of the bleeding phenotype in the
clinical and research setting; however, they have not been
widely validated for patients with inherited platelet func-
tion disorders. Therefore, specific cutoffs to define a pos-
itive bleeding score have not been established for this
population.18 This is of particular relevance in GT,
because while the types of bleeding are consistent among
individuals, the degree of bleeding is highly variable.
Given the severity of this disorder, historically, most
patients have been diagnosed in childhood (before 5 years
of age), but there are some patients that reach adulthood
without having severe bleeding.9 In general, the severity
of bleeding (except for menorrhagia and pregnancy-asso-
ciated bleeding) decreases with age.
Laboratory phenotype 
Complete blood count
There should be normal platelet count and size with
normal granularity on evaluation of the peripheral blood
smear by light microscopy. If bleeding is severe and/or
chronic, patients can have low hemoglobin, microcytosis
and increased red cell distribution width from secondary
iron deficiency. Other abnormalities of the complete
blood count (CBC), suggest an alternative diagnosis.
Coagulation screening tests
Routine tests ordered in the workup of a patient with
abnormal bleeding, such as prothrombin time (PT), acti-
vated thromboplastin time (aPTT) and fibrinogen, are
usually normal, unless a patient is being evaluated in the
setting of significant acute hemorrhage and has evidence
of consumptive coagulopathy.  
Platelet function screening tests
The platelet function analyzer (PFA)-100 provides a
measure of platelet function under high shear. It is con-
venient as it uses low volume whole blood samples and
is widely available to clinicians. Very prolonged closure
times (>300 seconds) are compatible with GT but not
specific, as other disorders, such as severe von Willebrand
disease, Bernard Soulier syndrome and afibrinogenemia,
can produce the same result.  However, a normal PFA-100
has a very high negative predictive value for GT  and vir-
tually excludes this diagnosis.19
Platelet light transmission aggregometry
Despite its limited availability and the need for larger-
volume samples and immediate processing, platelet light
transmission aggregometry (LTA) remains the gold stan-
dard in the clinical diagnosis of GT. It is based on the
decreased turbidity generated by platelet agglutinates or
aggregates in platelet rich plasma after exposure to differ-
ent agonists. Decreased/absent aggregation (<10%) with
all physiologic agonists, together with a normal aggluti-
nation response to ristocetin (mediated by GPIb-IX-V), is
the classic pattern observed in patients with GT.20 Due to
the large variability in platelet aggregation results and the
significant effect of pre-analytical variables on this test,
confirmation of the findings in a second sample is recom-
mended. 
Whole blood impedance aggregometry
This is available in several centers worldwide. While it
can be performed in whole blood samples and using
lower volumes, there is not enough evidence to support
equivalent sensitivity and reproducibility when com-
pared to LTA.21 There is some clinical utility to this test in
cases in which access to LTA is difficult; however,
patients should preferably be referred for evaluation at a
center that has LTA capacity at least once to confirm the
diagnosis. 
Platelet glycoprotein expression study by flow cytometry
This assesses quantitative platelet surface glycoprotein
deficiencies using fluorescent-conjugated antibodies that
are specific towards GP.22 This test can be performed in
low sample volumes shipped for analysis; however, it
will not identify type III (functional) defects that are
caused by qualitative but not quantitative defects in
GPIIb/IIIa (Figure 1). 
Differential diagnosis 
Leukocyte adhesion deficiency type III
Leukocyte adhesion deficiency type III (LAD-III) is an
autosomal recessive disorder caused by pathogenic vari-
ants in the kindlin 3 gene FERMT323 that also presents fail-
ure of the “inside-out” integrin activation in platelets,
white cells and endothelial cells,11 causing bleeding, infec-
tions and impaired wound healing. Due to the functional
integrin defect affecting platelets, these patients have the
same platelet aggregation pattern as those with GT and
similar to type III (variant) GT, but have normal platelet
glycoprotein expression by flow cytometry. The associat-
ed neutrophil dysfunction leading to frequent bacterial
infections and impaired wound healing in patients with
LAD-III may help clinicians distinguish these patients
from those with GT. 
RASGRP2 related platelet dysfunction
RASGRP2 encodes calcium and diacylglycerol-regulat-
ed guanine exchange factor I (CalDAG-GEFI), a protein
that also participates in “inside out” signaling of integrins.
Pathogenic variants in this gene lead to autosomal reces-
sive non-syndromic platelet dysfunction characterized by
moderate to severe bleeding and decreased platelet aggre-
gation with ADP and epinephrine, and, in some cases,
arachidonic acid, collagen and thrombin.24
Bernard Soulier syndrome
Bernard Soulier syndrome (BSS) is also an autosomal
recessive disorder caused by pathogenic variants in
GP1BA, GP1BB and GP9. The clinical presentation in
terms of bleeding phenotype is very similar to GT; how-
ever, BSS is relatively easy to distinguish due to
macrothrombocytopenia, platelet LTA with normal
aggregation with all agonists except ristocetin, and pro-
tein assessment (e.g. flow cytometry) showing
decreased/absent CD42a (GPIX) and CD42b (GPIb-
alpha). 
Acquired Glanzmann thrombasthenia
Acquired GT is typically caused by antibodies with
specificity against GPIIb/IIIa (or nearby epitopes) that
block the interaction of the receptor with fibrinogen and
von Willebrand factor. It presents with late-onset, severe
mucocutaneous bleeding in the setting of normal platelet
counts25 and is usually secondary to autoimmune, lym-
phoproliferative or plasma cell disorders. Medications,
specifically anti-thrombotics that block GPIIb/IIIa such as
abciximab, eptifibatide and tirofiban, have also been
implicated.26 The absence of lifelong bleeding and pres-
ence of concomitant systemic disorder should lead the cli-
nician to suspect this diagnosis. 
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Figure 1. Typical laboratory phenotype in Glanzmann thrombasthenia (GT). 
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Molecular confirmation 
Genetic analysis is clinically useful for confirmation of
the diagnosis, identification of at-risk carriers, reproduc-
tive risk counseling for a given couple/family, and for
definitive prenatal or preimplantation genetic diagnosis.
Genetic counseling plays an essential role in the genetic
testing process, obtaining informed consent regarding the
unique considerations, benefits, and limitations of genetic
testing, and addressing the complexities of clinical appli-
cation or molecular findings, unexpected results, variants
of uncertain significance, and familial implications for
medical risks or biological relationships. Genetic coun-
Figure 2. Diagnostic flow chart for the laboratory evaluation of a patient with suspected Glanzmann thrombasthenia (GT). 
selors can support clinicians by providing pre- and post-
test genetic counseling to patients and families in the clin-
ical setting, and can also aid clinicians in test selection and
ordering, and in navigating the process of obtaining insur-
ance approval for payment. This is particularly relevant in
healthcare systems with multiple payers and multiple
testing options. As commercial laboratories offer different
services, the clinician should be familiar with the testing
methodology and any related limitations. 
Given the highly specific phenotype of GT, after
platelet aggregation studies and flow cytometry have
been performed, genetic testing of ITGA2B and ITGB3
only, as opposed to a panel approach that includes multi-
ple other genes, is appropriate (Figure 2). Sequence analy-
sis will detect the vast majority of pathogenic variants;
when sequencing fails to identify both pathogenic vari-
ants in a patient with GT, specific deletion/duplication
analysis should be considered. 
Targeted variant analysis, which is expected to save
time and money, can be performed in populations with a
known pathogenic variant(s) and high rates of consan-
guinity; however, with this approach, a second GT vari-
ant in the same gene may go undetected.27 Targeted vari-
ant analysis is best adopted when the pathogenic variant
in each allele has been identified in an affected individual. 
Variant curation and initiatives for standardization 
In recent years, several initiatives have been taken to
provide guidance for the analysis and reporting of molec-
ular findings, specifically in terms of variant classification
when attributing pathogenicity. In the United States, the
American College of Medical Genetics and Genomics
(ACMG) and Association for Molecular Pathology (AMP)
published guidelines in 2015 for the interpretation of vari-
ants, providing a framework for clinical molecular labora-
tories.14 While these guidelines have been extremely use-
ful in the laboratory practice, they are not disease specif-
ic, and significant challenges remain when applied to par-
ticular disease states. In an effort to address this limita-
tion, and to improve the quality, consistency and access
to clinical genomic data, the National Institutes of Health
(NIH) funded resource ClinGen is leading initiatives
including the formation of Variant Curation Expert Panels
(VCEP). Each VCEP consists of a cross-institutional team
of experts from complementary specialties, the fields of
hematology and genetics, from academia and industry,
working collaboratively with the goal of adapting the
ACMG criteria for specific genes or disorders.28
The Platelet Disorder Variant Curation Expert Panel
(VCEP) created in 2018 and supported by the American
Society of Hematology, is composed of 28 international
scientists and clinicians with expertise in hematology and
genetics, and has been working on the adaptation of the
ACMG rules for the interpretation of variants in ITGA2B
and ITGB3. The goals of this collaboration are to produce
high quality variant curation data that are publicly avail-
able and create a framework for GT variant curation that
allows others to systematically and comprehensively
approach genetic data encountered in clinical and
research settings. 
The VCEP has used estimates of prevalence and popu-
lation data to define criteria for allele frequency that ulti-
mately serve as standalone, strong or supporting evidence
to classify variants as benign, which is a difficult task in
rare disorders for which the precise incidence data are not
available. Clinical expertise was key in defining the phe-
notype from a clinical presentation (bleeding phenotype)
and clinical laboratory standpoint (platelet aggregation
and glycoprotein expression studies), which together are
unique to GT. Knowledge of the molecular biology of the
disorder allowed for elimination of codes that do not
apply for this disease state and points for segregation
analysis were modified taking into account the disease
inheritance, low frequency and specific clinical pheno-
type. Special consideration was given to defining the type
of assays that provide quality functional evidence in dif-
ferent in vivo and in vitro systems and models.  The disease
specified rules were tested in a subset of variants which
will be uploaded to ClinVar with a 3-star rating. Variants
assessed by approved ClinGen VCEP also receive a US
Food and Drug Administration (FDA) approval label. A
detailed description of the rule specifications for GT will
soon be available to the public. 
Management 
Patients with GT benefit from being managed at a center
with expertise in inherited bleeding disorders, with access
to staff who are able to provide recommendations and
J. Perez Botero et al.
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Table 1. Measures and medications available for the management of bleeding in Glanzmann thrombasthenia (GT). 
Treatment                                                                Clinical situation
Local measures                                                                    Mild bleeding at a visible/compressible site 
• Compression 
• Gauze or sponge dipped in antifibrinolytic or topical thrombin
• Nasal packing
• Gel foam soaked in antifibrinolytic or topical thrombin
Antifibrinolytics                                                                    As monotherapy in mild bleeding 
• Tranexamic acid
• Aminocaproic acid                                                            As combination therapy in moderate and severe bleeding 
rFVIIa                                                                                       Moderate to severe bleeding 
                                                                                                  Alone for minor surgical procedures or in combination with antifibrinolytics and/or platelet 
                                                                                                  transfusions for major procedures and severe or life-threatening bleeding 
Platelet transfusion*                                                           In combination with rFVIIa and/or antifibrinolytics in severe bleeding and major surgical procedures
rFVIIa: recombinant activated coagulation factor VII. *Risk of lack of efficacy in the setting of alloimmunization.
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treatment any time of day, and also benefit from being pro-
vided directly with medical alerts, and emergency medical
contact and treatment information to present when seek-
ing urgent care from clinicians who are not familiar with
their case history. Education on avoidance of over-the-
counter medications that increase bleeding risk such as
non-steroidal anti-inflammatories and aspirin products
should be provided. Prescription medications that can
affect hemostasis should be carefully monitored.29
Hemostatic management 
The treatment of bleeding in patients with GT includes
management of acute or chronic bleeding and prevention
of hemorrhagic complications around the time of proce-
dures. The choice of treatment depends on the severity of
bleeding (Table 1), availability of products, and prior
responses to therapy, and is similar in some aspects to the
management of patients with other severe bleeding disor-
ders. Note that desmopressin (DDAVP), commonly used
in von Willebrand Disease and other milder disorders of
platelet function, is of limited clinical utility in the treat-
ment of GT (Table 1). 
Recombinant activated factor VII (rFVIIa) is approved
by the European Medicines Agency (EMA) and the FDA
for the treatment of patients with GT. The approval of
this drug has changed the landscape of treatment of GT
and has allowed for better hemostatic outcomes in all
patients, especially those who do not respond to platelet
transfusions. Optimal dosing and interval of doses vary
by center and clinical situation. Typical doses for acute
bleeding are 90 mcg/kg intravenous (IV) every 2-6 hours
until hemostasis is achieved (at least 3 doses).
Perioperative dosing is 90 mcg/kg immediately before
surgery and every two hours during the procedure, with
doses every 2-6 hours postoperatively to prevent post-
surgical bleeding.30 Effectiveness of this drug in the treat-
ment of acute bleeding is high31 when started early in the
course of bleeding and used in combination with other
hemostatic treatment. It is also useful for perioperative
management.32 Although cases of thromboembolism dur-
ing rFVIIa therapy in GT patients have occurred, it
remains a safe medication in this population, with low
rates of adverse reactions. 
Transfusion 
Patients with GT have a high risk of development of
isoantibodies, with up to 30% of patients developing anti-
GPIIb/IIIa or anti-HLA antibodies after platelet
transfusion.33 Patients with pathogenic variants causing
premature stop codons and leading to absent GPIIb/IIIa are
at the highest risk of anti GPIIb/IIIa alloimmunization
compared to those with other types of variants (81% vs.
25%).34 Once these antibodies develop, the patient may no
longer respond to platelet transfusion. For this reason,
platelet transfusions should be reserved for only major sur-
geries, life-threatening bleeding, and significant bleeding
that does not respond to the above measure. Transfusions
in women of reproductive age should ideally be avoided as
the antibodies can cross the placenta and affect the fetus.35
Bone marrow transplant
Allogeneic stem cell transplantation has been success-
fully performed in selected patients with severe recurrent
bleeding using reduced intensity conditioning with good
clinical outcomes.36,37 The presence in the recipient of
antiplatelet antibodies affecting the graft remains a chal-
lenge in this patient population.38
Pregnancy 
Pregnant women with GT have a high rate of compli-
cations and are best managed in a specialized center with
a multidisciplinary team. While most complications relate
to bleeding and occur at the time of delivery, manage-
ment of the pregnant GT patients should start in the pre-
natal period. Counseling of the pregnancy-associated
risks and screening of the father in consanguineous fami-
lies to identify at-risk fetuses is important. Identification
of HLA or GPIIb/IIIa antibodies during pregnancy, which
are present in up to 70% of patients, is key for planning
delivery. In general, regional anesthesia is contraindicated
and support with rFVIIa and antifibrinolytics is given for
vaginal deliveries with the option of adding platelet trans-
fusion for cesarian sections.39 Primary post-partum hem-
orrhage is common, and a large proportion of women will
require red cell transfusion. Clinicians should be aware
that, given the phenotypic variability of this disorder,
around half the women with GT who are pregnant may
not be aware of the diagnosis.35
Future directions 
Gene therapy is highly promising in providing a cure
for patients with GT, with significant progress made
using different techniques, vectors and model organ-
isms.40-42 However, further advances that allow safe trans-
gene delivery and stable expression in human models are
still required.33
Ongoing challenges   
Despite advances in the understanding of the patho-
physiology, the relative ease of access to clinical laborato-
ry techniques, and recent improvements in treatment
options (such as rFVIIa), many challenges remain in the
care of patients with this rare disorder. Access to clini-
cians and laboratories with the required expertise and
resources to diagnose and treat GT is difficult, especially
in areas of the world with limited resources. Large-scale
data analysis and clinical research are problematic given
the limited numbers of patients available and the highly
constrained funding for rare disorders. Initiatives through
the World Federation of Hemophilia for clinical care and
multinational collaborations including the Glanzmann
Thrombasthenia Registry for analysis of clinical out-
comes, and sharing of molecular data through creation of
publicly accessible databases have taken important steps
in bridging the gaps. However, more investment is need-
ed to guarantee timely access to quality care, until a true
cure for the disease is developed. 
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